Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Esketamine ...

You won’t drive or do other tasks that require an alert mind on the day of your dose. No, Spravato is not the same drug as ketamine. The active ingredient in Spravato is esketamine. There is ...

and a safety follow-up through 2 weeks after the last dose of trial treatment (Fig. S1). After the screening phase, patients were randomly assigned, in a 1:1 ratio, to receive esketamine nasal ...

The FDA said this is the first time esketamine was approved for any use ... be monitored for "at least two hours" after receiving a dose and can't drive for the rest of the day.

One low dose injection of esketamine administered right after childbirth reduces major depressive episodes in those with prenatal depression, according to a new study. When considering ketamine ...

Spravato (esketamine) is a nasal spray used for depression ... spray and you plan to use this the same day as your Spravato dose, take the steroid or decongestant nasal spray at least an hour ...

More information: Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial, The BMJ (2024). DOI: 10.1136/bmj-2023-078218 ...

It compared nasal esketamine to only one other drug. Other drugs used to augment treatment in patients with treatment-resistant depression include low-dose lithium, thyroid medication, atypical ...

The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an ...